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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the comparative efficacy and tolerability of different content and delivery cognitive behavioural therapy (CBT) components,
and combination of components of CBT for the treatment of depression in adults using a component-level network meta-analysis.
B A C K G R O U N D
Description of the condition
Major depressive disorder is one of the most common forms of
mental disorder and is characterised by low mood and a dimin-
ished interest in pleasurable activities. Individuals can experience a
range of symptoms including weight loss or weight gain, a decrease
or increase in appetite, insomnia or hypersomnia, psychomotor
agitation or retardation, fatigue, loss of energy, diminished concen-
tration or ability to think, feelings of worthlessness or of inappro-
priate guilt, disruptions to decision making, and morbid thoughts
of death (APA 2013).
The global burden of depression has risen greatly over the past few
decades, and it is now estimated that 350 million people world-
wide are affected by the disorder (World Health Organization
2016). As the leading cause of disability worldwide (World Health
Organization 2016), depression is associated with marked per-
sonal, social and economic morbidity, loss of functioning and pro-
ductivity, and high levels of service use (NICE 2009).
Description of the intervention
Cognitive behavioural therapy (CBT) is the most commonly re-
searched psychological therapy for the treatment of depression
(Hofmann 2008). CBT can be regarded as a ‘family’ of related
therapies (Mansell 2008), and may be delivered in many forms.
Treatment protocols variously incorporate a range of different
components such as psychoeducation, cognitive restructuring, be-
havioural activation, and problem solving. These may be used
alone or in multiple combinations, often depending on patient
formulation. Evidence suggests that CBT is an efficacious treat-
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ment for depression and its use is recommended by the National
Institute for Health and Care Excellence (NICE 2009).
As a family of complex interventions consisting of various thera-
peutic components, CBT can be delivered in a number of ways.
Whilst more usually provided in a traditional face-to-face setting
(as either individual or group therapy), CBT can also be delivered
with via multi-media platforms. Multi-media delivered CBT can
be defined as any standardised CBT approach that is delivered us-
ing one, or a combination of, the following multimedia platforms:
self-help books, audio or video recordings, telephone, computer
programmes (both online and desktop), Apps, e-mail, or text mes-
sages. These therapies can be provided with varying amounts of
therapist interaction. Some approaches defined as ‘self-help’ are
designed to be completed almost entirely independent of profes-
sional contact, with the individual working through the therapy
programme at their own pace with only technical help provided
(Bower 2001). In guided self-help CBT, an individual is given
access to a standardised CBT programme and works through it
more or less independently but with support provided by a ther-
apist. The support tends to be of supportive or facilitative nature,
and is meant to support the patient in working through the CBT
programme (Cuijpers 2010). In guided self-help CBT, the inter-
action between patient and therapist can take place by telephone,
email, text message, or any other communication method. More
recently, blended treatments have been developed with the aim
of preserving the personal contact and therapeutic relationship
that occurs in traditional face-to-face therapy, whilst maintaining
the benefits of increased accessibility that come with multi-media
delivered therapies (Kenter 2015; Kooistra 2016). Blended pro-
grammes combine real-time therapist interaction - conducted ei-
ther face-to-face or remotely - with multi-media deliveredmaterial
to form one treatment (e.g. Hoifodt 2013; Kessler 2009;Månsson
2013).
How the intervention might work
CBT is based onBeck’s cognitivemodel of depression (Beck 1976).
The model proposes that problematic experiences in early life can
make an individual vulnerable to depression through the develop-
ment of negative core beliefs about the self, others and the world.
These core beliefs can be triggered later in life by stressful events.
During episodes of depression, information processing is affected,
leading to biased and negative interpretation of interpersonal ex-
periences, with an increased sense of isolation and reduced levels
of activity (Grant 2004).
Cognition is central to the treatment of depression in CBT, with
emotions and behaviour thought to be mediated by cognitive pro-
cesses. CBT approaches are based on three fundamental propo-
sitions that cognitive activity affects behaviour, that cognitive ac-
tivity can be monitored and altered, and that desired behaviour
change may be affected through cognitive change (Dobson 2001).
In CBT, therapists work collaboratively with individuals to help
them identify, explore and modify relationships between nega-
tive thinking, behaviour and depressed mood. This is achieved by
learning to identify and monitor the intensity of different moods,
recognising the thoughts and behaviours that have contributed to
this mood, and learning how to address these by evaluating and
challenging unhelpful thoughts and engaging in behaviour that
contributes to improved mood. Cognitive change in depression
is achieved by targeting negative automatic thoughts (immediate
and plausible negative thoughts based on faulty schema that are
not arrived at through reflective reasoning) using techniques such
as thought catching, reality testing, task assignment and generating
alternative strategies ( Williams 1997). Behavioural experiments
are then used to re-evaluate underlying beliefs and assumptions
(Bennett-Levy 2004).
Why it is important to do this review
Currently there is little understanding about which components,
combinations of components, and modes of delivery are the most
effective at reducing depression. It is possible that treatment effects
are yielded by a certain components beyond which the addition of
other componentsmight add little or no benefit. Attempts to assess
the efficacy of different components/combinations of components
of CBT for depression have largely taken the form of dismantling
studies (Christensen 2006; Jacobson 1996; Vázquez 2015), where
one group of individuals receive a particular CBT component or
combination of components, and are comparedwith an alternative
combination. In this design, two combinations of components
can be directly compared.
The aim of this review is to compare the efficacy and tolerability of
components and combinations of components - commonly used
in CBT - and delivered via a range of platforms, using a compo-
nent level network meta-analysis (NMA). NMA (also known as
’Multiple treatment meta-analysis’ or ’Mixed Treatment Compar-
isons’) is a form of meta-regression that facilitates the concurrent
comparison of multiple interventions in a single analysis. Using
a connected network, this statistical strategy allows all pairwise
effects to be estimated, even in the absence of direct evidence,
while at the same time respecting the randomisation of the ev-
idence (Bucher 1997). NMA has been extended and used suc-
cessfully to estimate the relative effectiveness and acceptability of
different process and content components, and combinations of
components of interventions, by fitting additive and interaction
models (Caldwell 2016; Welton 2009a). In this review, we plan
to categorise components and combinations of components of
CBT for depression by using amethod adapted from other reviews
involving qualitative assessment of the intervention information
provided in the trial reports (Faggiano 2008; Hetrick 2015). We
will then complete a NMA at the component level.
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O B J E C T I V E S
To assess the comparative efficacy and tolerability of different con-
tent and delivery cognitive behavioural therapy (CBT) compo-
nents, and combination of components of CBT for the treatment
of depression in adults using a component-level network meta-
analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Clinical characteristics of included studies have been chosen to
reflect, as far as possible, the context in which CBT is actually
delivered.
We will include randomised controlled trials (RCT); cluster-ran-
domised trials; and though an unlikely methodology to use in this
area, we will also include any cross-over trials. For cross-over trials,
only the results of the first active treatment phase will be included
in our analysis.
Types of participants
Participant characteristics
Adults between 18 and 74 years will be included (studies that in-
clude adults above 74 years of age will be included where the av-
erage age is 74 or below). A broad age range has been chosen to
reflect the age group likely to be offered CBT for their depression.
The increasing prevalence of memory decline (Ivnik 1992), cog-
nitive impairment (Rait 2005) and multiple comorbid physical
disorders/polypharmacy (Chen 2001) in individuals over 74 years
may differentially influence the process and effect of psychological
therapy interventions, especially those delivered via a multimedia
format. The effects of different components and different meth-
ods of delivery in individuals over 74 are deserving of a standalone
review.
Diagnosis
We will include studies of participants receiving treatment during
an acute phase of depression. The acute phase could be a first
episode, or a relapse.
1. Studies adopting any standardised diagnostic criteria to
define participants suffering from an acute phase unipolar
depressive disorder will be included. Accepted diagnostic criteria
include Feighner criteria, Research Diagnostic Criteria, DSM-III
(APA 1980), DSM- III-R (APA 1987), DSM-IV-TR (APA
2000), DSM-5 (2013) or International Classification of Diseases
(ICD-10) (WHO 1992) criteria.
2. In order to fully represent the broad spectrum of severity of
depressive symptoms encountered in outpatient/ primary care
settings (Mitchell 2009; Rait 2009; Roca 2009), studies that use
non-operationalised diagnostic criteria, or a validated depression
symptom questionnaire to identify depression based on a
recognised threshold will also be included. Studies using both
clinician-rated (e.g. Hamilton Rating Scale for Depression
(Hamilton 1960)) or participant-rated (e.g. Beck Depression
Inventory (Beck 1961)) symptom questionnaires will be eligible
for inclusion. The influence of including studies that use a non-
operationalised diagnostic criteria will be examined in a
sensitivity analysis.
Co-morbidities
Studies involving participants with comorbid physical or common
mental disorders will be eligible for inclusion, as long as the comor-
bidity is not the focus of the study. For example, we will exclude
studies that focus on depression among patients with Parkinson’s
disease or after acute myocardial infarction, but will accept studies
that may have included some participants with Parkinson’s disease
or with acute myocardial infarction.
Setting
Studies may be conducted in primary care and community-based
settings, or in secondary or specialist settings, and will include
referrals as well as volunteers. Studies involving inpatients will be
excluded. Studies that focus on specific populations - nurses, care
givers, depressed participants at a specific work place - will be
included if the participants all meet the criteria for depression.
Types of interventions
Wewill include in our network studies that compare the following,
broadly categorised, interventions.
1. Face-to-face CBT: provided in either an individual or group
format.
2. Multi-media delivered CBT: we define multi-media
delivered psychological therapy as any standardised CBT
approach that is delivered via one, or more of the following
multimedia platforms: self-help books, audio or video
recordings, telephone, computer programmes (both online and
desktop), apps, e-mail, or text messages. Multi-media delivered
therapies can be provided with varying amounts of therapist
interaction broadly defined as self-help, guided self-help, and
blended treatment.
i) Self-help CBT: individuals work through the CBT
programme entirely independently, or with only minimal help
provided where necessary regarding technical aspects such as
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navigating the programme. These treatments are most likely to
be delivered via self-help books, audio or video recordings, or
computer programmes.
ii) Guided self-hep: individuals receive some level of
guidance from clinical practitioners. This guidance could be in
the form of e-mail or text message reminders, assessment of
homework via e-mail, or scheduled telephone calls.
iii) Blended CBT: integrated delivery of CBT through a
mixture of real-time therapist contact and multi-media delivered
materials. Real-time therapist contact could be conducted face-
to-face or remotely (e.g. via Skype, or instant messaging).
3. Treatment as usual: in each study, descriptions of ’treatment
as usual’ and attention placebo conditions will be scrutinised to
ensure that they do not comprise an active psychological therapy
treatment. Comparators will be subgrouped as follows.
i) Usual care or no treatment (UC).
ii) Waiting list (WL); participants receive assessment at
the point of randomisation and are told that they will receive the
active treatment after waiting for a specific duration.
iii) Attention placebo (AP); any form of inactive
intervention designed by the original authors to be perceived as
ineffective by patients.
iv) Psychological placebo (PP); any form of inactive
intervention designed by the original authors to be perceived as
effective by patients. The inclusion of an intervention among
attention or psychological placebo groups requires the
intervention to be inactive.
Within the ’treatment as usual’ and waiting list conditions, partic-
ipants may receive any appropriate medical care during the course
of the study on a naturalistic basis, including pharmacotherapy
and/or psychological therapy, as deemed necessary by the clini-
cian.
Participants within the active treatment arms of the trials may
receive anti-depressant medication on a naturalistic basis, however
we will exclude studies where combination treatment is provided.
Any additional treatment in both the active and control conditions
for each included study will be documented.
Identification of intervention components
Components are the active ingredients of interventions, and can
be considered at both a content and process/ delivery level.We will
use the constant comparative method (CCM) to identify compo-
nents of CBT interventions described in the CBT for depression
literature (Hetrick 2015). CCM is an iterative and inductive pro-
cess of reducing data into common categories or themes through
constant recoding. We will apply CCM to published trial reports
and accompanying process evaluations, coding the components,
or combination of components involved. As such, it is not possible
to specify components in advance, however, examplesmay include
a cognitive or behavioural activation content component and a
face-to-face or computer-delivered format. Identified components
will be discussed with a panel of clinical psychologists, therapists
and clinicians to arrive at an agreed nomenclature and to generate
a final taxonomy for components of CBT interventions.The tax-
onomy will be reported in the main review.
Types of outcome measures
Wewill estimate the relative ranking of the intervention, interven-
tion components, or combinations of components where possible,
according to the primary outcomes:
Primary outcomes
1. Treatment efficacy: the number of patients who respond to
treatment, based on changes on Beck Depression Inventory
(BDI) (Beck 1961), Hamilton Rating Scale for Depression
(HAM-D) (Hamilton 1960) or Montgomery-Asberg Depression
Rating Scale (MADRS) (Montgomery 1979), or any other
validated depression scale. Many studies define response by 50%
or greater reduction on BDI, HAM-D etc. but some studies
define response using Jacobson’s Reliable Change Index; we will
accept the study authors’ original definition. If the original
authors report several outcomes corresponding with our
definition of response, we will give preference to BDI for self-
rating scale and HAM-D for observer-rating scale.
2. Treatment acceptability: the number of participants who
drop out of treatment for any reason.
Secondary outcomes
1. The number of patients who achieve remission. Remission
status will be assessed based on the endpoint status of
participants, as measured using the BDI (Beck 1961), BDI-II
(Beck 1996), HAM-D; (Hamilton 1960) or MADRS;
(Montgomery 1979), or any other validated depression scale.
Examples of definitions of remission include 10 or less on BDI,
seven or less on HAM-D or 10 or less on MADRS; we will
accept and record study authors’ definitions of remission.
2. Improvement in depression symptoms as measured by a
change in depression scores using the DSM-IV-TR (APA 2000)
or ICD-10 (WHO 1992) or other validated diagnostic
instruments, for example HAM-D (Hamilton 1980), BDI-II
(Beck 1996), Hospital Anxiety and Depression Scale (HADS)
(Zigmond 1983) and Geriatric Depression Scale (GDS) (Sheikh
1986).
3. Adverse events as reported by the authors, including
incidence of self-harming behaviour, completed suicide,
attempted suicide, and worsening of behaviour.
4. Quality of life measured using validated measures such as
the EQ-5D (EuroQol group 1990) SF-36 (Ware 1993), Health
of the Nation Outcome Scale (HoNOS; Wing 1998) and The
World Health Organization Quality of Life (WHOQL 1998).
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Timing of outcome assessment
We will extract outcomes measured post-treatment and at follow-
up. We will categorise outcomes as short term (up to six months
post-treatment), medium term (seven to 12 months post-treat-
ment), and long term (longer than 12 months post-treatment).
When authors measure outcomes at multiple time points within
a pre-defined period, we will include only the longest time point
after randomisation.
Hierarchy of outcome measures
When several possible outcome measures are reported for the same
outcome, we will use the primary outcome according to the orig-
inal study.
Search methods for identification of studies
Electronic searches
We will search MEDLINE (1950-), Embase, (1974-), PsycINFO
(1967-) and the Cochrane Central Register of Controlled trials
(CENTRAL) via the specialised register of the Cochrane Com-
mon Mental Disorders Group (CCMDCTR) to 10-June-2016.
This register contains over 40,000 reports of RCTs for common
mental disorders, collated from repeat, generic searches of the core
biomedical databases (a search based on Population and RCT filter
only) (Appendix 1). For the purpose of this network meta-analy-
sis, we will include studies identified from three separate searches
of the CCMDCTR, for a suite of Cochrane reviews (Churchill
2013; Hunot 2010; Hunot 2013). Each search will use a sensitive
list of terms for intervention (Appendix 2).
We will run additional searches of Ovid MEDLINE, Embase,
PsycINFO and the Cochrane Central Register of Controlled Trials
(CENTRAL) (directly) from 2016 onwards, to complement the
searches of the CCMDCTR.
Wewill not apply any restrictions on date, language or publication
status to the searches.
We will search International trial registries via the World Health
Organization’s trials portal (ICTRP) and ClinicalTrials.gov to
identify unpublished or ongoing studies.
Searching other resources
Reference lists
Wewill check the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches (for example unpublished or in-press
citations).
Correspondence
We will contact trialists and subject experts for information on
unpublished or ongoing studies or to request additional trial data.
Data collection and analysis
Selection of studies
Two review authors will independently assess titles and abstracts
for relevance.Wewill code abstracts as ’retrieve’ or ’do not retrieve’.
Wewill thenfind the full-text papers for all abstracts coded retrieve.
The full-text papers will be assessed for inclusion independently by
two review authors. Conflicts will be resolved through discussion,
or by consultationwith a third review author. Reasons for exclusion
will be noted. Multiple reports of the same study will be tagged
together. We will record the study selection is sufficient detail to
produce a PRISMA flow diagram.
Data extraction and management
We will extract from each study the number of participants who
responded to treatment as measured using the BDI ((Beck 1961),
(HAM-D) (Hamilton 1960) or MADRS (Montgomery 1979),
or any other validated depression scale. We will also extract the
number of participants and the number of dropouts; the number
of participants classed as having achieved remission; change in
depression symptom scores measured using the DSM-IV-TR (
APA 2000) or ICD-10 (WHO1992) or other validated diagnostic
instruments, for example HAM-D (Hamilton 1980), BDI-II (
Beck 1996), HADS (Zigmond 1983) and GDS (Sheikh 1986);
adverse events; and quality of life measured by EQ-5D (EuroQol
group 1990) SF-36 (Ware 1993), Health of the Nation Outcome
Scale (HoNOS;Wing 1998) and TheWorldHealthOrganization
Quality of Life (WHOQL 1998).
Data on potential effect modifiers
We will extract the following study, intervention and population
characteristics from each study as they may act as effect modifiers.
1. Baseline symptom severity
2. Gender
3. Participant age
4. Duration of treatment
5. Length of follow up
6. Proportion of participants with comorbidities
7. Year of trial publication
8. Number of previous episodes of depression
9. Antidepressant use
At least two review authors will independently extract data from all
included studies using a structured excel data collection form. Any
disagreements in the extraction process, including determining the
constituent components of the interventions, will be resolved by
consultation with a third member of the author team.
5The process and delivery of cognitive behavioural therapy (CBT) for depression in adults: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
the included trials using the approach described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements will be resolved either through discussion or by
consulting a third author. We will assess the risk of bias according
to the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We will judge each potential source of bias as high, low, or un-
clear and provide a supporting quotation from the study report
together with a justification for our judgement in the ’Risk of bias’
table. We will assess blinding for outcome assessment separately
for objective-rated outcomes and those rated subjectively.
We will judge each potential source of bias as high, low, or un-
clear and provide a supporting quotation from the study report
together with a justification for our judgement in the ’Risk of bias’
table. We will assess blinding for outcome assessment separately
for objective-rated outcomes and those rated subjectively.
Measures of treatment effect
Continuous outcomes
Where studies use the same outcome measure for comparison,
data will be pooled by calculating the mean difference (MD), or
standardised mean difference (SMD) if values across trials on the
same scales vary greatly.When different measures are used to assess
the same outcome, data will be pooled using the SMD, or we will
map between outcomes using the approach described by (Ades
2015). We will also calculate and report 95% confidence intervals
(95% CIs).
Dichotomous data
Dichotomous outcomes will be analysed where possible by calcu-
lating using a pooled odds ratio (OR). We will also calculate and
report 95%CIs.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials only if the intracluster
correlation coefficient (ICC) is reported or can be borrowed from
similar trials.We will estimate the effect size in cluster-randomised
trials using the ICC to adjust for cluster effects as described in the
Cochrane Handbook for Systematic Reviews of Interventions, section
16.4.3 (Higgins 2011).
Cross-over trials
Cross-over trials will only be included in the calculation of sum-
mary statistics when it is possible to extract intervention and com-
parator data from the first treatment period.
Dealing with missing data
In the case of missing outcome data, we will contact study authors
to request the relevant data. Where authors are unable to provide
the information, we will impute the missing values as follows.
Dichotomous outcomes
Missing dichotomous data will be managed assuming that patients
who dropped out after randomisation had a negative outcome
i.e. non-response. Best-/worse-case sensitivity analyses will also be
conducted e.g. assuming that dropouts in the active treatment
group had positive outcomes and those in the control group had
negative outcomes (best-case scenario), and that dropouts in the
active treatment group had negative outcomes and those in the
control group had positive outcomes (worst-case scenario), thus
providing boundaries for the observed treatment effect. If there
is a large amount of missing information then these best-/ worst-
case scenarios will be given greater emphasis in the presentation
of the results.
Continuous outcomes
Missing continuous data will either be analysed on an endpoint
basis, including only participants with a final assessment, or anal-
ysed using last observation carried forward to the final assessment
(LOCF), if LOCF data were reported by the trial authors. Where
standard deviations (SDs) are missing, attempts will be made to
obtain these data through contacting trial authors. Where SDs are
not available from trial authors, they will be calculated from P
values, t-values, CIs or standard errors (SEs) , where reported in
articles (Deeks 1997).
Where the vast majority of actual SDs are available and only a
minority of SDs are unavailable or unobtainable, we will estimate
them based on a prediction from a hierarchical model for SDs
from those studies that did report them. Here we assume that any
missing SD is exchangeable (i.e. broadly similar) with the reported
SDs. We will also undertake a sensitivity analysis to examine the
effect of the decision to use imputed data.
Where additional figures are not available or obtainable, and it is
not deemed appropriate to use the Furukawa method described
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above, the study data will not be included in the comparison of
interest.
Assessment of heterogeneity
Pairwise meta-analyses
We will assess clinical heterogeneity by looking for obvious differ-
ences between participants, interventions and outcomes.
Assessment of transitivity across treatment comparisons
The assumption of transitivity (also known as consistency) is in-
tegral to network meta-analysis (NMA). Transitivity suggests that
intervention A is comparable when in studies comparing A versus
B, and A versus C. Transitivity can be assessed by examining the
distribution of potential effectmodifiers across comparisons in the
network.
To evaluate the assumption of transitivity, we will extract study
level characteristics considered to be potential effect modifiers (see
above, baseline symptom severity, gender, participant age, duration
of treatment, length of follow-up, proportion of participants with
comorbidities, and year of trial publication), and examine their
similarity visually using cross tabulations.
Assessment of reporting biases
For pairwise comparisons that include 10 or more studies, we will
visually examine funnel plots for signs of reporting bias and small-
study effects.
Data synthesis
All analyses will be undertaken in a Bayesian framework using
OpenBUGS ( www.openbugs.net), freely available software. Prior
distributions will be reported.We will assess convergence based on
two chains using the Brooks-Gelman-Rubin diagnostic plots and
visually using history plots available in OpenBUGS. The number
of iterations run as ‘burn-ins’ pre-convergence and the subsequent
iterations will be reported.
Methods for indirect and mixed comparisons
We will conduct a NMA in order to simultaneously compare the
interventions. In its simplest form a NMA is a combination of
direct and indirect estimates of relative treatment effects in one
single analysis. An indirect comparison enables the estimation of
the effect of treatment B relative to treatment A via a common
comparator C by statistically combining the summary effects from
’A versus C’ and ’B versus C’ studies ( Caldwell 2005; Glenny
2005). Through the combination of direct and indirect evidence
across a network of studies, a NMA can make inferences regarding
the relative effectiveness of multiple interventions.
Given the nature of the included interventions, we expect some
clinical heterogeneity between studies and therefore plan to use
a random-effects model for all analyses. We will examine a fixed-
effect model as a sensitivity analysis. For analysis at the interven-
tion-level, a random-effects NMA will be conducted, taking into
account the correlations induced by multi-arm trials (Dias 2010;
Lu 2004). For each comparison, the posterior mean effect estimate
along with its 95% credible interval (CrI) will be reported. For the
component level analysis, we will use the meta-regression mod-
els developed by Welton 2009b and will evaluate four models: a
single-effect model (akin to standard meta-analysis), an additive
main-effects model, a 2-way interaction model (allowing pairs of
components to have either a bigger or smaller effect than would
be expected from the sum of their effects alone) and a full-interac-
tion model. We will fit models to different degrees of detail in the
definitions of the components, data allowing and we will compare
the model fit.
In addition to producing relative treatment effects for each com-
parison, NMAs allow an estimate of the relative ranking of inter-
ventions. We will rank interventions using a mean rank.
Methods for direct treatment comparisons
At the intervention-level, we will perform random-effects pairwise
meta-analyses for each direct comparison for which there are two,
or more, trials. The method of estimation for the pairwise analyses
will be identical to the NMA, except we do not apply the consis-
tency assumption, such that we obtain separate intervention-effect
estimates for each pairwise comparison. We also assume that the
heterogeneity parameter is common across intervention compar-
isons.
Subgroup analysis and investigation of heterogeneity
For each pairwise, direct comparison we will report τ 2, the be-
tween-trial variability in treatment effects (heterogeneity) and the
I2.
NMA assumes that the network has consistency, or that direct
and indirect evidence are in agreement. However, this assumption
can be violated either in the entire network or in certain parts of
the network (i.e. loops of evidence) (Bucher 1997). To evaluate
consistency, we will employ three strategies at the level of the
treatment.
Model fit will be measured using the posterior mean of the residual
deviance, which is a measure of the magnitude of the difference
between the observed data and the model predictions for those
data. Smaller values are preferred, and in a well-fitting model the
posterior mean residual deviance should be close to the number
of data points. We will also report the effective number of pa-
rameters, PD and Deviance Information Criteria (DIC), which
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penalises model fit with model complexity. In comparing mod-
els, differences of ≥ 5 points for posterior mean residual deviance
and DIC will be considered meaningful, with lower values being
favoured (Welton 2009b). As a global check of consistency, we
will compare the fit of a NMA model assuming consistency with
a model that allows for inconsistency (also known as an unrelated
treatment-effect model) (Dias 2013). If the inconsistency model
has the smaller posterior mean residual deviance, heterogeneity, or
DIC value, then this may indicate potential inconsistency in the
data. If evidence of inconsistency is identified, thenwe will explore
this further using node-splitting methods, where the direct and
indirect estimates for a particular contrast are estimated separately
(effectively relaxing the consistency assumption for a particular
contrast) and then compared to form a node-split P value.
We will use the above strategy, together with an evaluation of
between-study heterogeneity, in our assessment of consistency.
Sensitivity analysis
Sensitivity analyses will be conducted, excluding studies at high
risk or unclear risk of bias on the allocation concealment and
blinding domains of Cochrane’s’Risk of bias’ assessment tool. Ad-
ditional sensitivity analyses include:
1. fixed-effect analyses for the pairwise and network meta-
analyses will be run;
2. trials where missing data were imputed will be removed;
3. trials that use a non-operationalised diagnostic criteria will
be removed;
4. waiting list will be removed from the network.
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Appendix 1. OVID Medline: CCMD’s core search strategy used to inform the specialised register
Description of the Specialised Register of the Cochrane Common Mental Disorders Group (CCMD-CTR)
The Cochrane Common Mental Disorders Group maintained a specialised register of randomized controlled trials at the University of
Bristol to June 2016. This register contains over 40,000 reference records (primary and secondary reports of RCTs) for anxiety disorders,
depression, bipolar disorder, eating disorders, self-harm and other common mental disorders which fall within the scope of the CCMD
Group. The CCMD-CTR is a partially studies based register with 50% of the reference records tagged to c12,500 individually PICO
coded study records. Reports of trials for inclusion in the register were collated from (weekly) generic searches of Medline (1950-),
Embase (1974-) and PsycINFO (1967-), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and
review specific searches of additional databases. Reports of trials were also sourced from international trial registries, drug companies,
the hand-searching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses. Details
of CCMD’s core (generic) search strategies (used to identify RCTs) can be found on the Group’s website (http://cmd.cochrane.org/).
By way of example, the MEDLINE search (used to inform the CCMD-CTR) is displayed below.
[N.B. In July 2016 the Cochrane Common Mental Disorders Group moved to the University of York.]
CCMD Core MEDLINE Search (a weekly Ovid search alert based on population and RCT filter only)
1. [MeSH Subject Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or agoraphobia/
or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disorders/ or stress
disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/ or anxiety/ or anxiety,
castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body dysmorphic disorders/
or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ ormunchausen syndrome by proxy/ ormunchausen syndrome/
or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse control disorders/
or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual dysfunctions,
psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Keywords]:
eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or
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parasuicid* or mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic
or cyclothymic* or depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety
disorder* or agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform
or somati#ation or medical* unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or
munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder*
or mental health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random*
adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or
place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or
study or studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or
clinical trial, phase iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental
or random*)).ti,ab. or ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
[Field Tags: ti-title; ab-abstract; kf-keyword heading word]
Records were screened for reports of RCTs within the scope of CCMD. Primary and secondary reports of RCTs were tagged to the
appropriate study record. Similar weekly search alerts were also conducted on OVID EMBASE and PsycINFO, using relevant subject
headings (controlled vocabularies) and search syntax, appropriate to each resource.
Appendix 2. Search strategies
Search 1: Psychological therapies for depression A broad search of all psychological therapies for depression, for the HIRED-MAP
project (High Impact Reviews of Effectiveness in Depression - Meta-analysis of Psychological Therapies).
1a. CCMDCTR-Studies (all years to 1-January-2012, updated 10-April-2014)
#1 (depress* or dysthymi*):sco and (*therap* or train*):sin
[Search fields: sco:health care condition; sin:intervention]
1b. CCMDCTR-References (all years to 1-January-2012, updated 10-April-2014)
#1 (therap* or psychotherap*):ti,ab
#2 (psychotherapy):kw,ky,mh,emt
#3 (acceptance* or commitment* or “activity scheduling” or adlerian or art or aversion or brief or “client cent*” or cognitive or color
or colour or compassion-focused or “compassion focus*” or compassionate or conjoint or conversion or conversational or couples or
dance or dialectic* or diffusion or distraction or eclectic or (emotion and focus*) or emotion-focus* or existential or experiential or
exposure or expressive or family or focus-oriented or “focus oriented” or freudian or gestalt or “group” or humanistic or implosive or
insight or integrative or interpersonal or jungian or kleinian or logo or marital or metacognitive or meta-cognitive or milieu or morita
or multimodal or multi-modal or music or narrative or nondirective or non-directive or “non directive” or nonspecific or non-specific
or “non specific” or “object relations” or “personal construct” or “person cent*” or person-cent* or persuasion or play or ((pleasant
or pleasing) and event*) or primal or problem-focused or “problem focused” or problem-solving or “problem solving” or process-
experiential or “process experiential” or psychodynamic or “rational emotive” or reality or “reciprocal inhibition” or relationship* or
reminiscence or restructuring or rogerian or schema* or self-control* or “self control*” or “short term” or short-term or sex or “social
effectiveness” or “social skill*” or socio-environment* or “socio environment*” or “solution focused” or solution-focused or “stress
management” or supportive or time-limited or “time limited” or “third wave” or transference or transtheoretical or validation) [all
fields]
#4 (abreaction or “acting out” or “age regression” or ((assertive* or autogenic or mind or sensitivity) and train*) or autosuggestion or
“balint group” or ((behavior* or behaviour*) and (activation or therap* or treatment or contracting or modification)) or biofeedback
or catharsis or cognitive or “mind training” or counsel* or “contingency management” or countertransference or “covert sensitization”
or “eye movement desensiti*” or “crisis intervention” or “dream analysis” or “emotional freedom” or “free association” or “functional
analys*” or griefwork or “guided imagery” or hypno* or imagery or meditation* or “mental healing” or mindfulness* or psychoanaly*
or psychodrama or psychoeducat* or “psychological support*” or “psychosocial support*” or “social support*” or “family support*”
or psychotherap* or relaxation or “role play*” or “self analysis” or “self esteem” or “sensitivity training” or (support* and group*) or
therapist or “therapeutic technique*” or “transactional analysis”) [all fields]
#5. ((#1 or #2) and #3) or #4
#6. (depress* or dysthymi*):ti,ab
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#7. Tagged to CCMDCTR-Study=empty
[Search fields: ti:title; ab:abstract; kw:Cochrane Review Group (CRG) keywords; ky: other keywords; emt: EMTREE headings; mh:
MeSH headings]
Search 2: Cognitive behavioural therapies versus treatment as usual for depression
A cross-search of CCMD-CTR-Sudies and CCMD-CTR-References Registers. (10-Apr-2014 to 7-Aug-2015, updated 6-June-2016)
[N.B. Prior to this date, studies were identified from the global HIRED-MAP searches, detailed above]
#1. ((cognitive NEAR2 (behavi* or modif* or restructur* or intervention or treatment* or *therap* or train*))) [all fields]
#2. cognitive:ti
#3. (*CBT* or cognitive-behavi*) [all fields]
#4. (RET OR PST):ab
#5. (problem-sol* or “problem sol*” or psychoeducat* or psycho-educat* or psychodrama or psycho-drama* or “rational emotive” or
“reality *therap*” or “role play*” or schema or schemas or schemata)
#6. (self-control or (self* NEAR2 (control or efficacy))) [all fields]
#7. “stress manage*” [all fields]
#8. (group NEXT (*therap* or program* or treatment))[all fields]
#9. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10. depress*:ti
#11. (depression or depressive):kw,ky,mh,emt
#12. (depress* and (Beck* or BDI* or DSM* or “Diagnostic and Statistical Manual of Mental Disorders” or Hamilton or HAM-D or
HAMD or “International Classification of Diseases” or ICD-10)):ab
#13. (MDD or (depress* NEAR2 (diagnos* or episode* or disorder or major or scale* or score* or unipolar))):ab
#14. (#10 or #11 or #12 or #13)
#15. (#9 and #14)
#16. (treatment-as-usual or (treatment* NEAR2 usual) or (standard NEAR2 care) or (routine NEAR2 care) or (usual NEAR2 medi-
cation*) or (usual NEAR2 care) or TAU):ti,ab
#17. (waitlist* or wait-list* or waiting-list* or “wait* list*” or (waiting next (condition or control)) or WLC):ti,ab
#18. (“delayed treatment*” or “no treatment*” or “non treatment*” or nontreatment* or “minim* treatment*” or “untreated group*”
or “untreated control*” or “without any treatment”):ti,ab
#19. (untreated NEAR3 (patients or participants or subjects or group* or control*)):ti,ab
#20. (“no intervention*” or non intervention* or non-intervention* or without any intervention*):ti,ab
#21. (“receiv* nothing” or “standard control”):ti,ab
#22. (“no therap*” or “non therap*” or nontherap* or “minim* therap*” or “no contact” or pseudotherap* or “therap* as usual” or
“usual therap*”):ti,ab
#23. (“reference group” or “observation group”):ti,ab
#24. (“convention* treatment” or “conventional *therap*” or “standard treatment*”):ti,ab
#25. (#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#26. (#15 and #25)
Search 3: Multimedia-delivered cognitive behavioural therapy versus face-to-face cognitive behavioural therapy for depression in adults
(All years to 10-June-2016)
A cross-search of CCMD-CTR-Sudies and CCMD-CTR-References Registers.
#1 (“chat room*” or distance* or etherap* or e-therap* or “instant messag*” or iCBT* or i-CBT or cCBT or c-CBT or internet* or
web* or www* or online* or on-line* or mHealth or multimedia* or multi-media* or mobile or email* or e-mail* or remote or texting
or “text message” or SMS or telehealth* or telemed* or telepsych* or teletherap* or tele-therap*) [all fields]
#2 (android or app or apps or cellphone* or “cell phone*” or “digital device*” or “digital technolog*” or iphone* or i-phone* or ipad*
or i-pad* or “mobile phone” or smartphone or “smart phone”) [all fields]
#3 (MoodGym* or “Mood Gym” or “Beat* the Blues”) [all fields]
#4 (computer* near (*CBT* or cognitive)):ti,ab
#5 (ecompared or e-compared) [all fields]
#6 (blended or bCBT) [all fields]
#7 (DVD or CD-ROM or CDROM) [all fields]
#8 ((manual or book or booklet or leaflet or pamphlet) and (*face* or therapist* or psychotherap*))
#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10 (depress* or mood or dysthymi* or “affective disorder*” or “affective symptom*”):ti,ab,kw,ky,mh,mc,emt
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#11 (#9 and #10)
#12 telephone [all fields]
#13 #12 and #10
#14 #11 or #14
Search 4: ’Third wave’ cognitive and behavioural therapies versus treatment as usual for depression
(1-Feb-2013, updated 9-July-2015 and 6-June-2016)
[N.B. Prior to this date, studies were identified from the global HIRED-MAP searches, detailed above]
A cross-search of CCMD-CTR-Sudies and References Register
#1 depress*:ti,ab,kw,ky,mh,mc,emt
#2 (mindfulness* or “third wave” or third-wave or (*therap* and (acceptance* or commitment*)) or experiential or (cognitive* and
(restructur* or defusion)) or (behavio* and (activation or modification)) or (thought* and suppress*) or rumination) [All Fields]
#3 (#1 and #2)
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